Premature birth and later insulin resistance

New England Journal of Medicine

Volumn 351, Issue 21, 2004, Pages 2179-2186

  Hofman, Paul L ^a   Regan, Fiona ^a   Jackson, Wendy E ^a   Jefferies, Craig ^a   Knight, David B ^c   Robinson, Elizabeth M ^b   Cutfield, Wayne S ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c NATIONAL WOMEN S HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; BIRTH WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR;

BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, SMALL FOR GESTATIONAL AGE; INSULIN RESISTANCE; LINEAR MODELS; MALE; RISK FACTORS;

EID: 6444225735     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa042275     Document Type: Article

References (32)

1. Hales CN, Barker DJ, Clark PM, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991;303:1019-22.
2. Barker DJ. Fetal growth and adult disease. Br J Obstet Gynaecol 1992;99:275-6.
3. Idem. The long-term outcome of retarded fetal growth. Clin Obstet Gynecol 1997;40:853-63.
4. Idem. In utero programming of chronic disease. Clin Sci (Lond) 1998;95:115-28.
5. Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002;31:1235-9.
6. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298:564-7.
7. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989;2:577-80.
8. Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301:1111.
9. Hofman PL, Cutfield WS, Robinson EM, et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 1997;82:402-6.
10. Gray IP, Cooper PA, Cory BJ, Toman M, Crowther NJ. The intrauterine environment is a strong determinant of glucose tolerance during the neonatal period, even in prematurity. J Clin Endocrinol Metab 2002;87:4252-6.
11. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-8.
12. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-9.
13. Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994;23:Suppl:I-12-I-15.
14. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-13.
15. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
16. Auckland District Health Board. Section 5. Newborn services. National women's annual report 2000. (Accessed October 25, 2004, at http://www.adhb.govt. nz/newborn/Research/Publications/AnnualReport2000. pdf.)
17. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. Natl Vital Stat Rep 2002;50:1-101.
18. Cutfield WS, Bergman RN, Menon RK, Sperling MA. The modified minimal model: application to measurement of insulin sensitivity in children. J Clin Endocrinol Metab 1990;70:1644-50.
19. Guaran RL, Wein P, Sheedy M, Walstab J, Beischer NA. Update of growth percentiles for infants born in an Australian population. Aust N Z J Obstet Gynaecol 1994;34:39-50.
20. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
21. DuRant RH, Linder CW. An evaluation of five indexes of relative body weight for use with children. J Am Diet Assoc 1981;78:35-41.
22. McLaren DS, Read WW. Weight/length classification of nutritional status. Lancet 1975;2:219-21.
23. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
24. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-7.
25. Boyko EJ. Proportion of type 2 diabetes cases resulting from impaired fetal growth. Diabetes Care 2000;23:1260-4.
26. Roseboorn TJ, van der Meulen JH, Ravelli AC, Osmond C, Barker DJ, Bleker OP. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. Mol Cell Endocrinol 2001;185:93-8.
27. Bloomfield FH, Oliver MH, Hawkins P, et al. A periconceptional nutritional origin for noninfectious preterm birth. Science 2003;300:606.
28. Vickers MH, Breier BH, Cutfield WS, Hofman PL, Gluckman PD. Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab 2000;279:E83-E87.
29. Petry CJ, Ozanne SE, Wang CL, Hales CN. Effects of early protein restriction and adult obesity on rat pancreatic hormone content and glucose tolerance. Horm Metab Res 2000;32:233-9.
30. Nyirenda MJ, Welberg LA, Seckl JR. Programming hyperglycaemia in the rat through prenatal exposure to glucocorticoids - fetal effect or maternal influence? J Endocrinol 2001;170:653-60.
31. Bazaes RA, Alegria A, Pittaluga E, Avila A, Iniguez G, Mericq V. Determinants of insulin sensitivity and secretion in very-low-birth-weight children. J Clin Endocrinol Metab 2004;89:1267-72.
32. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.